Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.82 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078275 | 0.90 | NAMPT (1.00) | NAMPTSLC2A1NPC1RAB9AMEN1 | |
| SCHEMBL1078986 | 0.88 | NAMPT (0.78) | NAMPTSLC2A1MEN1KMT2AMAPT | |
| SCHEMBL998913 | 0.85 | NAMPT (0.64) | NAMPTSLC2A1NPC1RAB9AMEN1 | |
| SCHEMBL1043110 | 0.85 | NAMPT (0.76) | NAMPTSLC2A1NPC1RAB9AMEN1 | |
| SCHEMBL11300274 | 0.85 | NAMPT (0.79) | NAMPTSLC2A1NPC1RAB9AMEN1 | |
| SCHEMBL1048408 | 0.84 | NAMPT (0.75) | NAMPTSLC2A1NPC1RAB9AMEN1 | |
| SCHEMBL1049301 | 0.84 | NAMPT (0.75) | NAMPTSLC2A1NPC1RAB9AMEN1 | |
| SCHEMBL11306726 | 0.82 | NAMPT (0.71) | NAMPTSLC2A1NPC1RAB9AMEN1 | |
| SCHEMBL996338 | 0.81 | TSHR (0.67) | NAMPTSLC2A1NPC1MEN1KMT2A | |
| SCHEMBL11303710 | 0.80 | TSHR (0.65) | NAMPTSLC2A1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079859-B2 | Synthetic lethal targeting of glucose transport | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-14 | — | — | US | claimed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | claimed |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | RUGA CORPORATION | 2014-05-08 | — | — | US | claimed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | claimed |
| US-9079859-B2 | Synthetic lethal targeting of glucose transport | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-14 | — | — | US | disclosed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | RUGA CORPORATION | 2014-05-08 | — | — | US | disclosed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | BRDT, NISCH, PAICS | NAMPT 624/4885SLC2A1 4252/4885NPC1 2057/4885 |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | SLC2A1, SLC2A3, SLC2A2 | NAMPT 601/4885SLC2A1 1/4885NPC1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.